Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 3/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | HTR2B | P41595 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9213520 | 0.91 | P2RX7 (0.53) | LMNAOPRM1DRD3CHRM2CHRM4 | |
| SCHEMBL4246056 | 0.91 | DRD3 (0.66) | LMNAOPRM1DRD3CHRM2ADRA2A | |
| SCHEMBL4249527 | 0.90 | DRD3 (0.61) | LMNAOPRM1DRD3CHRM2CHRM4 | |
| SCHEMBL3631349 | 0.88 | DRD2 (0.63) | LMNADRD3DRD2SIGMAR1P2RX7 | |
| SCHEMBL9216002 | 0.87 | OPRD1 (0.54) | LMNAOPRM1OPRD1ALDH1A1MAPK1 | |
| SCHEMBL7287223 | 0.85 | KMT2A (0.62) | LMNAOPRM1DRD3CHRM2CHRM4 | |
| SCHEMBL10760285 | 0.84 | DRD2 (0.64) | LMNADRD3CYP2D6DRD2SIGMAR1 | |
| SCHEMBL6163028 | 0.84 | HRH1 (0.64) | LMNAOPRM1DRD3CHRM2CHRM4 | |
| SCHEMBL9217851 | 0.84 | OPRD1 (0.54) | LMNAOPRM1KMT2AOPRD1MEN1 | |
| Hydrochloric Acid SCHEMBL7280236 | 0.84 | MEN1 (0.60) | LMNAOPRM1DRD3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024233922-A2 | PYRIDINE-PIPERAZINE-BASED SCAFFOLDS AS HIGHLY POTENT AND SELECTIVE NEUROLYSIN ACTIVATORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | disclosed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | disclosed |
| CN-1149214-C | Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient | ������������ʽ���� | 2004-05-12 | — | — | CN | disclosed |
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-5324728-A | Lipoxygenase inhibiting antiallergens | FUJIREBIO INC. (JP) | 1994-06-28 | — | — | US | disclosed |
| US-5164391-A | Treatment of diabetes and circulatory disorders, aldose reductase inhibitor | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1992-11-17 | — | — | US | disclosed |
| EP-0492178-A2 | Naphthoic acid derivative | FUJIREBIO INC. (JP) | 1992-07-01 | — | — | EP | disclosed |
| EP-0463873-A1 | Thiazolidinecarboxylic acid amide derivatives having anti-allergic activity, their preparation and their use | Sankyo Company Limited (JP) | 1992-01-02 | — | — | EP | disclosed |
| EP-0143001-B1 | PYRIMIDOISOQUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | disclosed |
| EP-0418834-A1 | Hydantoin derivatives for treating complications of diabetes and circulatory diseases | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1991-03-27 | — | — | EP | disclosed |
| US-4673684-A | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO CORPORATION (JP) | 1987-06-16 | — | — | US | disclosed |
| US-4673676-A | Pyrimidoisoquinoline derivatives useful for treating allergies | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-16 | — | — | US | disclosed |
| EP-0157420-A2 | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1985-10-09 | — | — | EP | disclosed |
| EP-0143001-A2 | Pyrimidoisoquinoline derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | LMNA 3551/4885OPRM1 377/4885DRD3 212/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | LMNA 3551/4885OPRM1 377/4885DRD3 212/4885 |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | LMNA 1425/4885OPRM1 438/4885DRD3 680/4885 |
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | LMNA 4037/4885OPRM1 212/4885DRD3 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.